Stock Spotlight Archives - Page 140 of 378

TuesdayNov 16, 2021 3:36 pm

QualityStocksNewsBreaks – PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) on Mission to Change How Consumers Define ‘Plant-Based’

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is driven by the objective to become the most-trusted name for people living plant-based lifestyles. The company provides a multifaceted marketplace offering plant-based products and services for consumers. “PlantX is on a mission to change how consumers define ‘plant-based’ by bringing together community, lifestyle and food,” reads a recent article. “Educating the public on how plant-based products can impact society is largely part of PlantX’s mission. The company works with the communities it serves to increase awareness and provide community members with the knowledge and education needed to understand the opportunities…

TuesdayNov 16, 2021 3:02 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities

InMed Pharmaceuticals (NASDAQ: INM) and its subsidiary BayMedica are innovators in the field of rare cannabinoids, making them available for consumer access. InMed specializes in developing a proprietary biosynthesis system to manufacture pharmaceutical-grade cannabinoids that are otherwise too rare to be acquired in abundance. Through BayMedica, its recent acquisition, InMed also has capabilities in both yeast biosynthesis and chemical synthesis, catering to the large and growing health and wellness consumer markets. “The cannabis plant is made up of over 100 unique cannabinoids, many of which are only found in trace amounts,” reads a recent article. “With so many of these…

MondayNov 15, 2021 12:31 pm

QualityStocksNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, including cellular and protein-level details, to determine the existence of cancerous environments. At present, the company’s CDA platform “can detect up to 26 different types of cancer, which gives AnPac Bio a major advantage over industry peers in terms of cost effectiveness, multi-cancer testing, ability…

MondayNov 15, 2021 12:09 pm

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Committed to Making Psychedelic Wellness Accessible to the Masses

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is well positioned to capitalize on the psychedelic industry’s continued growth trajectory. “The company owns and operates a self-sustaining ecosystem of businesses in the psychedelic space consisting of media, science and health business verticals. Delic has been particularly active on the mergers and acquisitions front over the last several months in a bid to further broaden the company’s business horizons,” reads a recent article. In March, the company acquired the brand and IP of Homestead, a legacy counterculture distributor of psychedelic media and creator of one of the first…

MondayNov 15, 2021 11:57 am

QualityStocksNewsBreaks – DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) Empowering Clients to Make Better Decisions Through Actionable Predictive Insight

DigiMax Global (CSE: DIGI) (OTC: DBKSF), a company that provides artificial intelligence (“AI”) and cryptocurrency technology solutions, is emerging as a leader in the AI world. Recently, Harvard Business Review (“HBR”) reported that AI could be instrumental, when combined with analytics, in alleviating skill shortages by creating solutions and augmenting support activities, as well as boosting productivity, delivering new products and services, and addressing supply chain issues. The HBR report predicts that the coming boom in business growth and innovation will be a data-driven one. “Next-generation technologies — artificial intelligence and analytics — will play a key role in boosting business…

MondayNov 15, 2021 11:26 am

QualityStocksNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Plans to Develop Next-Generation Hearing Products Following Acquisition

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, recently acquired all assets and operations of iHEAR Medical Inc., a venture-backed pioneer in online direct-to-consumer hearing solutions. INND expects the acquisition to expand and solidify its position as the emerging leader in the market of direct-to-consumer and over-the-counter hearing products. In addition, the acquisition offers InnerScope access to over 40 patents in hearing technology, brings world-class innovation and helps the company broaden its product offering. iHEAR, which has demonstrated a track record of bringing novel hearing solutions to the market, boasts a…

FridayNov 12, 2021 3:08 pm

QualityStocksNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently signed a non-binding letter of intent (“LOI”) with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing and delivering psychedelic medicine to treat addiction. “Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for alcohol use disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM,” reads a recent article. In addition to distributing its partners’ protocols, MINDCURE will also be distributing its own protocols through iSTRYM.…

FridayNov 12, 2021 11:32 am

QualityStocksNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Eyeing Q1 2022 Delivery of Highest-Quality Retail Products from Florida Grow Operations

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently completed phase one of an aggressive three-phase development strategy for its Florida facilities, located in Apopka and Sanderson. Phase one entailed the rapid development of the Apopka facility. RWB also announced that it had commenced operation in late September after receiving regulatory approval to begin cultivation. “The initial licensed area in Apopka is capable of producing 85g of flower per plant, translating to projected annual revenue in excess of $10 million. The Apopka facility will supply RWB’s phase two of the strategy, which entails activating thirty 16’ by 40’ customized,…

FridayNov 12, 2021 11:19 am

QualityStocksNewsBreaks – Excellon Resources Inc. (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) Reigniting Saxony’s Storied Mining History

Excellon Resources (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) is actively working to reignite the Saxony region’s proud and storied history, which has long been synonymous with silver mining. According to Ben Pullinger, SVP Geology and Corporate Development for Excellon, Saxony has become an important jurisdiction for the company over that past year. “In mid-2020, Excellon announced that it had entered into a research and development alliance with the Helmholtz Institute Freiberg (‘HIF’). The company’s team seeks to apply modern exploration technology on the historically significant Silver City mineral field in Saxony, Germany,” reads a recent article. Excellon, which holds…

ThursdayNov 11, 2021 1:30 pm

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters into Cannabinoid Science

Flora Growth Corp. (NASDAQ: FLGC) recently announced the next stage of its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma’s formation follows the acknowledgment and commitment by the management team and board of directors to move ahead with applied research initiatives in medical cannabis in order to become a leader in the discovery, development, manufacturing and commercialization of novel, phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of diseases. The company also signed an agreement to begin scientific clinical trials on the use of…

Site Search

Company Search

Category: Stock Spotlight